Abstract: Objective: To validate the prognostic value of an enhanced International Prognostic Index (NCCN- IPI) for diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP. Methods:A total of 168 DLBCL patients who were initially diagnosed and treated in Tianjin Medical University Cancer Institute and Hospital from January 2008to January 2013were included in the study. Baseline characteristics were collected, and survival analysis was performed using the standard IPI and the new NCCN-IPI model.Re-sults: The main clinical features were as follows: mean age was58(range: 24- 80) years old, 54.8% of them were male, 56% were stage Ⅲ/Ⅳdisease,11 .3% were Eastern Cooperative Oncology Group Performance Status (ECOG PS)≥ 2, and 71.4% had elevated lactate de-hydrogenase level (> 245 U/L). After a median follow- up of42(range: 15- 88) months, the 3- and 5- year overall survival (OS) rates were 75.9% ± 3.4% and65.1% ± 5.2%, respectively. According to the old IPI risk categorization,30.4%,27.4%,25.0%, and 17.3% pa-tients belonged to the four risk subgroups (low, low- intermediate, high- intermediate, and high). The corresponding percentages were 19.0% ,38.1% ,31.5% , and 11 .3% in the NCCN- IPI model. The3- year OS for the four NCCN- IPI risk groups were 94.5% ,85.4% ,61.2%, and 38.1%, respectively, whereas the rates were91.8%,76.7%,67.9%, and 47.1% for the IPI risk groups. Compared with the IPI, the NCCN-IPI better discriminated low- and high-risk subgroups ( 3-year OS: 94.5% vs.38.1%) than the IPI (3-year OS: 91.8% vs. 47.1% ), respectively. Conclusion:Compared with IPI, NCCN- IPI better incorporated two known prognostic variables, i.e., age and LDH, and was thus a more powerful prognosticator for DLBCL patients in the rituximab-based era.